Calcinosis cutis distrófica en enfermedades autoinmunitarias del tejido conjuntivo

Agustina Goglia; Gabriela Bendjuia

doi:10.47196/da.v26i3.2096

Autores/as

Agustina Goglia División Dermatología, Hospital General de Agudos José María Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina
Gabriela Bendjuia División Dermatología, Hospital General de Agudos José María Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v26i3.2096

Palabras clave:

calcinosis cutis, calcificación distrófica, enfermedades autoinmunitarias del tejido conjuntivo

Resumen

La calcinosis cutis distrófica puede ser una manifestación de múltiples enfermedades autoinmunitarias del tejido conjuntivo y causar desde un trastorno estético hasta una severa morbilidad. El estudio de la fisiopatogenia, donde se destaca el papel de la inflamación crónica, permite un abordaje terapéutico diverso y combinado para lograr mejores resultados y alienta el uso precoz e intensivo de antiinflamatorios.

Biografía del autor/a

Agustina Goglia, División Dermatología, Hospital General de Agudos José María Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina

Médica Dermatóloga, Hospital Ramos Mejía

Gabriela Bendjuia, División Dermatología, Hospital General de Agudos José María Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina

Médica de Planta, Sector Colagenopatías, Hospital Ramos Mejía

Citas

I. Jiménez-Gallo D, Ossorio-García L, Linares-Barrios M. Calcinosis cutis y calcifilaxis. Actas Dermosifiliogr 2015;106:785-794.

II. Reiter N, El-Shabrawi L, Leinweber B, et ál. Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol 2011;65:1-12.

III. Gutiérrez A, Wetter DA. Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther 2012;25:195-206.

IV. Valenzuela A, Chung L. Calcinosis: pathophysiology and management. Curr Opin Rheumatol 2015;27:542-548.

V. Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, et ál. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 2014;16:467-478.

VI. Chander S, Gondor P. Soft tissue and subcutaneous calcifications in connective tissue diseases. Current Opin Rheumatol 2012;24:158-164.

VII. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, et ál. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000;43:2368-2377.

VIII. Mamyrova G, O´Hanlon TP, Sillers L, Malley K, et ál. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008;58:3941-3950.

IX. Davies CA, Herrik AL, Cordingley L, Freemont A, et ál. Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis. Rheumatology (Oxford) 2009;48:876-882.

X. Davies CA, Jeziorska M, Freemont AJ, Herrik AL. Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Rheumatology (Oxford) 2006;45:1349-1355.

XI. Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM. Matrix Gla protein is regulated by a mechanism funcionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000;277:736-740.

XII. Van Summeren MJH, Spliet WGM, Van Royen-Kerkhof A, Vermeer C, et ál. Calcinosis in juvenile dermatomyositis: a possible role for the vitamin K-dependent protein matrix Gla protein. Rheumatology (Oxford) 2008;47:267-271.

XIII. Rothe MJ, Grant-Kels JM, Rothﬁeld NF. Extensive calcinosis cutis with systemic lupus erythematosus. Arch Dermatol 1990;126:1060-1063.

XIV. Winkelmann RK. Panniculitis in connective tissue disease. Arch Dermatol 1983;119:336-344.

XV. D'Aoust J, Hudson M, Tatibouet S, Wick J, et ál. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 2014;66:1608-1615.

XVI. Kimball AB, Summers RM, Turner M, Dugan EM, et ál. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum 2000;43:1866-1873.

XVII. Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol 2008;144:585-587.

XVIII. Riley P, McCann LJ, Maillard SM, Woo P, et ál. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008;47:877-880.

XIX. De Paula DR, Klem FB, Lorencetti PG, Muller C, et ál. Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 2013;32:281-283.

XX. Al-Mayouf SM, Alsonbul A, Alismail K. Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection. Int J Rheum Dis 2010;13:e26-28.

XXI. Taborn J, Bole GG, Thompson GR. Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann Intern Med 1978;8:648-649.

XXII. Balin SJ, Wetter DA, Andersen LK, Davis MDP. Calcinosis cutis occurring in association with autoimmune connective tissue disease. The Mayo Clinic Experience With 78 Patients, 1996-2009. Arch Dermatol 2012;148:455-462.

XXIII. Van Gelder JM, Breuer E, Ornoy A, Scholssman A, et ál. Anticalcification and antiresorption effects of bisacylphosphonates. Bone 1995;16:511-520.

XXIV. Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 2010;77:70-72.

XXV. Ambler GR, Chaitow J, Rogers M, McDonald DW, et ál. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005;32:1837-1839.

XXVI. Ratsimbazafy V, Bahans C, Guigonis V. Dramatic diminution of a large calcification treated with topical sodium thiosulfate. Arthritis Rheum 2012;64:3826.

XXVII. Ma JE, Ernste FC, Davis MDP, Wetter DA. Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017. Clin Exp Dermatol 2019;44:e189-e192.

XXVIII. Goossens J, Courbebaisse M, Caudron E, Bahans C, et ál. Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases. Semin Arthritis Rheum 2017;47:451-455.

XXIX. Dima A, Balanescu P, Baicus C. Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases. Rom J Intern Med 2014;52:55-67.

XXX. Chamberlain AJ, Walker NP. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbone dioxide laser. Dermatol Surg 2003;29:968-970.

XXXI. Sultan-Bichat N, Menard J, Perceau G, Staerman F, et ál. Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol 2012;66:424-429.